Loading
A phase 1 trial of Eganelisib run by Jacqueline Garcia, MD, now recruiting.
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia is a phase 1 interventional study registered as NCT07439211 by Jacqueline Garcia, MD, with 48 participants planned, started 2026-04-13. Conditions recorded: Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia and Refractory Leukemia. Interventions recorded: Eganelisib, Azacitidine and Venetoclax.
Shares Stelexis BioSciences, Eganelisib, Acute myeloid leukaemia and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Stelexis BioSciences, Eganelisib and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/